Share Price and Basic Stock Data
Last Updated: December 18, 2025, 1:04 pm
| PEG Ratio | -33.93 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Healthcare Global Enterprises Ltd (HCG) has carved a niche in the hospital and medical services sector, showcasing a robust revenue trajectory over the years. For the fiscal year ending March 2025, the company reported sales of ₹2,218 Cr, marking a commendable increase from ₹1,691 Cr in FY 2023. This upward trend in revenue is not merely a blip; it reflects consistent growth, as revenues have surged from ₹1,395 Cr in FY 2022. The quarterly sales figures also indicate a positive momentum, with revenues rising to ₹494.63 Cr in March 2024 from ₹441.71 Cr in the previous quarter. The company’s ability to scale operations while maintaining a steady influx of patients appears to be a core strength. However, it’s crucial to note that the healthcare sector is inherently cyclical and can be sensitive to economic fluctuations, which could impact future growth. Overall, HCG’s revenue growth signals a healthy demand for its services, driven by an expanding healthcare market in India.
Profitability and Efficiency Metrics
When we delve into HCG’s profitability, the numbers paint a mixed picture. The operating profit margin (OPM) for FY 2025 stood at 17%, a slight decline from 18% in FY 2024. This decrease, while not alarming, suggests that rising operational costs may be squeezing margins. The net profit for FY 2025 was recorded at ₹49 Cr, which is an improvement from ₹41 Cr in FY 2024, indicating that the bottom line is benefiting from increased revenues despite pressures on operating margins. Moreover, the company’s return on equity (ROE) was reported at 4.81%, which seems low compared to industry standards, hinting at the need for enhanced capital efficiency. On the efficiency front, the cash conversion cycle (CCC) is notably robust at -111 days, showcasing effective management of receivables and inventory. However, the relatively low ROE and fluctuating profit margins might raise concerns about sustainable profitability in the long term.
Balance Sheet Strength and Financial Ratios
HCG’s balance sheet reveals a company that is growing but is also facing challenges related to debt. The total borrowings as of March 2025 stood at ₹1,768 Cr, a significant increase from ₹901 Cr in FY 2022. This uptick in debt raises the total debt-to-equity ratio to 1.09, which could be viewed as a potential risk, especially in a rising interest rate environment. However, the interest coverage ratio (ICR) of 2.73x suggests that the company is still capable of meeting its interest obligations comfortably. The reserves have grown to ₹783 Cr, providing a cushion against financial volatility. Additionally, the book value per share increased to ₹66.16, reflecting a solid equity base. While HCG’s balance sheet shows signs of strengthening reserves, the rising debt levels warrant close scrutiny, as they could impact financial flexibility and future growth plans.
Shareholding Pattern and Investor Confidence
The shareholding pattern of HCG reveals a strong promoter backing, with promoters holding 63.78% of the shares as of September 2025. This level of commitment from the promoters is generally seen as a positive sign for investor confidence. However, foreign institutional investors (FIIs) have reduced their stake to 3.59%, down from 7.18% a couple of years ago, signaling a cautious stance from overseas investors. On the other hand, domestic institutional investors (DIIs) have steadily increased their holdings to 18.36%, reflecting a growing confidence among local institutions. The overall number of shareholders has also seen an uptick, reaching nearly 47,000, which could indicate increasing retail interest. This mixed sentiment among institutional investors, combined with strong promoter support, suggests a complex landscape for HCG, where investor confidence appears cautiously optimistic but is also tempered by external market factors.
Outlook, Risks, and Final Insight
Looking ahead, HCG seems well-positioned to capitalize on the growing healthcare demand in India, driven by an expanding middle class and increasing health awareness. However, several risks could impede its growth trajectory. The rising debt levels are concerning, especially if interest rates continue to climb, which could erode profitability. Additionally, fluctuations in operational costs may pressure margins further, especially in a post-pandemic world where healthcare demands can be unpredictable. Investors should also consider regulatory risks and market competition as potential headwinds. Ultimately, while HCG has demonstrated resilience and growth, careful monitoring of its financial health and market dynamics will be crucial. For investors, this stock represents both an opportunity and a challenge, necessitating a balanced approach to potential gains against the backdrop of inherent risks in the healthcare sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 41.6 Cr. | 124 | 194/120 | 8.48 | 117 | 2.82 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 22.6 Cr. | 21.5 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 8.56 Cr. | 8.29 | 20.8/8.13 | 95.2 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 113 Cr. | 60.1 | 98.7/55.2 | 24.8 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.4 Cr. | 3.59 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 25,763.43 Cr | 742.10 | 92.28 | 99.39 | 0.33% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 408.05 | 420.00 | 424.68 | 441.71 | 460.68 | 486.94 | 469.87 | 494.63 | 525.58 | 553.54 | 558.57 | 585.16 | 613.16 |
| Expenses | 335.89 | 345.31 | 349.18 | 365.40 | 386.37 | 402.32 | 391.26 | 402.60 | 434.68 | 451.30 | 470.19 | 479.53 | 505.37 |
| Operating Profit | 72.16 | 74.69 | 75.50 | 76.31 | 74.31 | 84.62 | 78.61 | 92.03 | 90.90 | 102.24 | 88.38 | 105.63 | 107.79 |
| OPM % | 17.68% | 17.78% | 17.78% | 17.28% | 16.13% | 17.38% | 16.73% | 18.61% | 17.30% | 18.47% | 15.82% | 18.05% | 17.58% |
| Other Income | 2.91 | 1.97 | 3.65 | 4.65 | 2.77 | 3.40 | 6.07 | 9.01 | 8.81 | 11.13 | 5.54 | 10.23 | 7.51 |
| Interest | 24.98 | 25.81 | 27.08 | 25.63 | 25.55 | 26.89 | 29.46 | 26.84 | 33.71 | 35.98 | 40.70 | 44.17 | 45.47 |
| Depreciation | 39.67 | 40.83 | 40.77 | 42.20 | 41.01 | 43.21 | 44.16 | 45.98 | 47.01 | 49.74 | 56.52 | 58.07 | 57.91 |
| Profit before tax | 10.42 | 10.02 | 11.30 | 13.13 | 10.52 | 17.92 | 11.06 | 28.22 | 18.99 | 27.65 | -3.30 | 13.62 | 11.92 |
| Tax % | 76.20% | 47.21% | 62.83% | 56.97% | 65.30% | 39.84% | 68.99% | 16.87% | 28.23% | 25.21% | -334.85% | 50.29% | 49.83% |
| Net Profit | 2.48 | 5.29 | 4.20 | 5.65 | 3.65 | 10.78 | 3.43 | 23.46 | 13.63 | 20.68 | 7.75 | 6.77 | 5.98 |
| EPS in Rs | 0.44 | 0.53 | 0.54 | 0.60 | 0.55 | 0.97 | 0.41 | 1.53 | 0.87 | 1.29 | 0.50 | 0.53 | 0.34 |
Last Updated: August 1, 2025, 8:20 pm
Below is a detailed analysis of the quarterly data for Healthcare Global Enterprises Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 613.16 Cr.. The value appears strong and on an upward trend. It has increased from 585.16 Cr. (Mar 2025) to 613.16 Cr., marking an increase of 28.00 Cr..
- For Expenses, as of Jun 2025, the value is 505.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 479.53 Cr. (Mar 2025) to 505.37 Cr., marking an increase of 25.84 Cr..
- For Operating Profit, as of Jun 2025, the value is 107.79 Cr.. The value appears strong and on an upward trend. It has increased from 105.63 Cr. (Mar 2025) to 107.79 Cr., marking an increase of 2.16 Cr..
- For OPM %, as of Jun 2025, the value is 17.58%. The value appears to be declining and may need further review. It has decreased from 18.05% (Mar 2025) to 17.58%, marking a decrease of 0.47%.
- For Other Income, as of Jun 2025, the value is 7.51 Cr.. The value appears to be declining and may need further review. It has decreased from 10.23 Cr. (Mar 2025) to 7.51 Cr., marking a decrease of 2.72 Cr..
- For Interest, as of Jun 2025, the value is 45.47 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 44.17 Cr. (Mar 2025) to 45.47 Cr., marking an increase of 1.30 Cr..
- For Depreciation, as of Jun 2025, the value is 57.91 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 58.07 Cr. (Mar 2025) to 57.91 Cr., marking a decrease of 0.16 Cr..
- For Profit before tax, as of Jun 2025, the value is 11.92 Cr.. The value appears to be declining and may need further review. It has decreased from 13.62 Cr. (Mar 2025) to 11.92 Cr., marking a decrease of 1.70 Cr..
- For Tax %, as of Jun 2025, the value is 49.83%. The value appears to be improving (decreasing) as expected. It has decreased from 50.29% (Mar 2025) to 49.83%, marking a decrease of 0.46%.
- For Net Profit, as of Jun 2025, the value is 5.98 Cr.. The value appears to be declining and may need further review. It has decreased from 6.77 Cr. (Mar 2025) to 5.98 Cr., marking a decrease of 0.79 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.34. The value appears to be declining and may need further review. It has decreased from 0.53 (Mar 2025) to 0.34, marking a decrease of 0.19.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:16 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 451 | 519 | 584 | 700 | 829 | 976 | 1,092 | 1,009 | 1,395 | 1,691 | 1,908 | 2,218 | 2,404 |
| Expenses | 413 | 443 | 499 | 595 | 713 | 864 | 936 | 887 | 1,161 | 1,394 | 1,581 | 1,835 | 1,979 |
| Operating Profit | 38 | 76 | 85 | 105 | 116 | 112 | 157 | 122 | 234 | 297 | 327 | 384 | 425 |
| OPM % | 9% | 15% | 15% | 15% | 14% | 11% | 14% | 12% | 17% | 18% | 17% | 17% | 18% |
| Other Income | 3 | 0 | -2 | 10 | 25 | 10 | 10 | -72 | 110 | 15 | 24 | 39 | 26 |
| Interest | 32 | 34 | 38 | 23 | 42 | 70 | 138 | 119 | 98 | 104 | 109 | 155 | 174 |
| Depreciation | 36 | 39 | 44 | 57 | 71 | 85 | 148 | 159 | 158 | 163 | 174 | 211 | 235 |
| Profit before tax | -27 | 3 | 0 | 35 | 27 | -33 | -119 | -229 | 88 | 45 | 68 | 57 | 42 |
| Tax % | 20% | -56% | -730% | 34% | 38% | -7% | 5% | -3% | 56% | 61% | 39% | 14% | |
| Net Profit | -32 | 5 | 2 | 23 | 17 | -31 | -125 | -221 | 39 | 18 | 41 | 49 | 41 |
| EPS in Rs | -5.21 | 0.12 | -0.17 | 2.59 | 2.36 | -2.82 | -12.03 | -15.43 | 3.87 | 2.11 | 3.46 | 3.19 | 2.52 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 115.62% | -60.00% | 1050.00% | -26.09% | -282.35% | -303.23% | -76.80% | 117.65% | -53.85% | 127.78% | 19.51% |
| Change in YoY Net Profit Growth (%) | 0.00% | -175.62% | 1110.00% | -1076.09% | -256.27% | -20.87% | 226.43% | 194.45% | -171.49% | 181.62% | -108.27% |
Healthcare Global Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 15% |
| 3 Years: | 17% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 52% |
| 5 Years: | 19% |
| 3 Years: | 73% |
| TTM: | -26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 42% |
| 3 Years: | 37% |
| 1 Year: | 70% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 0% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 5:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 68 | 70 | 85 | 86 | 87 | 88 | 89 | 125 | 139 | 139 | 139 | 139 | 141 |
| Reserves | 196 | 210 | 341 | 347 | 428 | 389 | 293 | 572 | 731 | 721 | 686 | 783 | 780 |
| Borrowings | 292 | 349 | 324 | 420 | 464 | 658 | 1,347 | 977 | 915 | 901 | 1,274 | 1,837 | 1,768 |
| Other Liabilities | 133 | 147 | 294 | 372 | 461 | 515 | 518 | 357 | 433 | 549 | 601 | 780 | 897 |
| Total Liabilities | 688 | 776 | 1,043 | 1,225 | 1,440 | 1,650 | 2,246 | 2,031 | 2,218 | 2,311 | 2,701 | 3,540 | 3,586 |
| Fixed Assets | 512 | 528 | 583 | 685 | 828 | 970 | 1,646 | 1,382 | 1,547 | 1,553 | 1,758 | 2,442 | 2,430 |
| CWIP | 11 | 42 | 121 | 148 | 174 | 153 | 46 | 30 | 22 | 18 | 83 | 25 | 96 |
| Investments | 2 | 0 | 64 | 11 | 53 | 49 | 34 | 26 | 9 | 10 | 10 | 11 | 13 |
| Other Assets | 164 | 205 | 275 | 381 | 385 | 478 | 520 | 593 | 641 | 730 | 850 | 1,062 | 1,048 |
| Total Assets | 688 | 776 | 1,043 | 1,225 | 1,440 | 1,650 | 2,246 | 2,031 | 2,218 | 2,311 | 2,701 | 3,540 | 3,586 |
Below is a detailed analysis of the balance sheet data for Healthcare Global Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 141.00 Cr.. The value appears strong and on an upward trend. It has increased from 139.00 Cr. (Mar 2025) to 141.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 780.00 Cr.. The value appears to be declining and may need further review. It has decreased from 783.00 Cr. (Mar 2025) to 780.00 Cr., marking a decrease of 3.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,768.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 1,837.00 Cr. (Mar 2025) to 1,768.00 Cr., marking a decrease of 69.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 897.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 780.00 Cr. (Mar 2025) to 897.00 Cr., marking an increase of 117.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,586.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,540.00 Cr. (Mar 2025) to 3,586.00 Cr., marking an increase of 46.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,430.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,442.00 Cr. (Mar 2025) to 2,430.00 Cr., marking a decrease of 12.00 Cr..
- For CWIP, as of Sep 2025, the value is 96.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 71.00 Cr..
- For Investments, as of Sep 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,048.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,062.00 Cr. (Mar 2025) to 1,048.00 Cr., marking a decrease of 14.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,586.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,540.00 Cr. (Mar 2025) to 3,586.00 Cr., marking an increase of 46.00 Cr..
However, the Borrowings (1,768.00 Cr.) are higher than the Reserves (780.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -254.00 | -273.00 | -239.00 | -315.00 | -348.00 | -546.00 | 156.00 | -855.00 | -681.00 | -604.00 | 326.00 | 383.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43 | 45 | 43 | 54 | 57 | 59 | 62 | 67 | 57 | 65 | 56 | 66 |
| Inventory Days | 33 | 36 | 32 | 40 | 46 | 45 | 35 | 32 | 31 | 33 | 33 | 33 |
| Days Payable | 193 | 208 | 264 | 272 | 274 | 303 | 234 | 221 | 199 | 214 | 216 | 210 |
| Cash Conversion Cycle | -117 | -127 | -188 | -178 | -171 | -200 | -136 | -121 | -112 | -116 | -127 | -111 |
| Working Capital Days | -20 | -65 | -96 | -112 | -74 | -110 | -102 | -26 | -43 | -40 | -70 | -91 |
| ROCE % | 1% | 7% | 6% | 7% | 6% | 3% | 1% | -1% | 5% | 8% | 9% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 4,400,000 | 0.47 | 321.35 | N/A | N/A | N/A |
| Nippon India ELSS Tax Saver Fund | 3,500,000 | 1.65 | 255.62 | N/A | N/A | N/A |
| Axis Small Cap Fund | 1,690,271 | 0.46 | 123.45 | N/A | N/A | N/A |
| Axis Flexi Cap Fund | 1,017,366 | 0.56 | 74.3 | N/A | N/A | N/A |
| Tata India Pharma & HealthCare Fund | 939,574 | 5.13 | 68.62 | 880,171 | 2025-12-15 01:12:28 | 6.75% |
| Tata Focused Fund | 758,709 | 2.95 | 55.41 | N/A | N/A | N/A |
| Motilal Oswal Balance Advantage Fund | 750,000 | 5.85 | 54.78 | N/A | N/A | N/A |
| Bandhan Large & Mid Cap Fund | 419,885 | 0.24 | 30.67 | N/A | N/A | N/A |
| Bandhan Midcap Fund | 203,141 | 0.75 | 14.84 | N/A | N/A | N/A |
| Axis Value Fund | 78,545 | 0.48 | 5.74 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.19 | 3.46 | 2.11 | 4.14 | -17.02 |
| Diluted EPS (Rs.) | 3.14 | 3.43 | 2.10 | 3.97 | -17.02 |
| Cash EPS (Rs.) | 18.61 | 15.46 | 13.02 | 14.29 | -4.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 66.16 | 59.28 | 61.86 | 63.57 | 56.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 66.16 | 59.28 | 61.86 | 63.57 | 56.96 |
| Revenue From Operations / Share (Rs.) | 159.44 | 136.97 | 121.58 | 100.55 | 80.84 |
| PBDIT / Share (Rs.) | 30.27 | 24.88 | 22.42 | 18.03 | 11.45 |
| PBIT / Share (Rs.) | 15.12 | 12.36 | 10.67 | 6.64 | -1.25 |
| PBT / Share (Rs.) | 4.03 | 4.83 | 3.23 | 6.42 | -18.21 |
| Net Profit / Share (Rs.) | 3.45 | 2.94 | 1.27 | 2.90 | -17.61 |
| NP After MI And SOA / Share (Rs.) | 3.19 | 3.46 | 2.11 | 3.87 | -15.43 |
| PBDIT Margin (%) | 18.98 | 18.16 | 18.43 | 17.93 | 14.16 |
| PBIT Margin (%) | 9.48 | 9.02 | 8.77 | 6.60 | -1.54 |
| PBT Margin (%) | 2.52 | 3.52 | 2.65 | 6.38 | -22.52 |
| Net Profit Margin (%) | 2.16 | 2.14 | 1.04 | 2.88 | -21.78 |
| NP After MI And SOA Margin (%) | 1.99 | 2.52 | 1.73 | 3.84 | -19.08 |
| Return on Networth / Equity (%) | 4.81 | 5.83 | 3.41 | 6.17 | -27.74 |
| Return on Capital Employeed (%) | 8.44 | 8.76 | 8.50 | 5.27 | -0.99 |
| Return On Assets (%) | 1.25 | 1.77 | 1.26 | 2.42 | -9.50 |
| Long Term Debt / Equity (X) | 0.65 | 0.58 | 0.42 | 0.41 | 0.49 |
| Total Debt / Equity (X) | 1.09 | 0.81 | 0.46 | 0.46 | 0.59 |
| Asset Turnover Ratio (%) | 0.71 | 0.75 | 0.74 | 0.46 | 0.31 |
| Current Ratio (X) | 0.80 | 0.91 | 1.02 | 1.07 | 0.93 |
| Quick Ratio (X) | 0.75 | 0.85 | 0.95 | 1.01 | 0.88 |
| Interest Coverage Ratio (X) | 2.73 | 3.19 | 3.01 | 2.56 | 1.20 |
| Interest Coverage Ratio (Post Tax) (X) | 1.31 | 1.34 | 1.17 | 0.44 | -0.06 |
| Enterprise Value (Cr.) | 8223.62 | 5119.81 | 3866.17 | 3975.48 | 2784.14 |
| EV / Net Operating Revenue (X) | 3.70 | 2.68 | 2.29 | 2.84 | 2.75 |
| EV / EBITDA (X) | 19.48 | 14.77 | 12.40 | 15.86 | 19.40 |
| MarketCap / Net Operating Revenue (X) | 3.37 | 2.47 | 2.16 | 2.68 | 2.36 |
| Price / BV (X) | 8.13 | 5.70 | 4.25 | 4.31 | 3.44 |
| Price / Net Operating Revenue (X) | 3.37 | 2.47 | 2.16 | 2.68 | 2.36 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | -0.08 |
After reviewing the key financial ratios for Healthcare Global Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.19. This value is below the healthy minimum of 5. It has decreased from 3.46 (Mar 24) to 3.19, marking a decrease of 0.27.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.14. This value is below the healthy minimum of 5. It has decreased from 3.43 (Mar 24) to 3.14, marking a decrease of 0.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 18.61. This value is within the healthy range. It has increased from 15.46 (Mar 24) to 18.61, marking an increase of 3.15.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.16. It has increased from 59.28 (Mar 24) to 66.16, marking an increase of 6.88.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.16. It has increased from 59.28 (Mar 24) to 66.16, marking an increase of 6.88.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 159.44. It has increased from 136.97 (Mar 24) to 159.44, marking an increase of 22.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 30.27. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 30.27, marking an increase of 5.39.
- For PBIT / Share (Rs.), as of Mar 25, the value is 15.12. This value is within the healthy range. It has increased from 12.36 (Mar 24) to 15.12, marking an increase of 2.76.
- For PBT / Share (Rs.), as of Mar 25, the value is 4.03. This value is within the healthy range. It has decreased from 4.83 (Mar 24) to 4.03, marking a decrease of 0.80.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 3.45. This value is within the healthy range. It has increased from 2.94 (Mar 24) to 3.45, marking an increase of 0.51.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.19. This value is within the healthy range. It has decreased from 3.46 (Mar 24) to 3.19, marking a decrease of 0.27.
- For PBDIT Margin (%), as of Mar 25, the value is 18.98. This value is within the healthy range. It has increased from 18.16 (Mar 24) to 18.98, marking an increase of 0.82.
- For PBIT Margin (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 10. It has increased from 9.02 (Mar 24) to 9.48, marking an increase of 0.46.
- For PBT Margin (%), as of Mar 25, the value is 2.52. This value is below the healthy minimum of 10. It has decreased from 3.52 (Mar 24) to 2.52, marking a decrease of 1.00.
- For Net Profit Margin (%), as of Mar 25, the value is 2.16. This value is below the healthy minimum of 5. It has increased from 2.14 (Mar 24) to 2.16, marking an increase of 0.02.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.99. This value is below the healthy minimum of 8. It has decreased from 2.52 (Mar 24) to 1.99, marking a decrease of 0.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.81. This value is below the healthy minimum of 15. It has decreased from 5.83 (Mar 24) to 4.81, marking a decrease of 1.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.44. This value is below the healthy minimum of 10. It has decreased from 8.76 (Mar 24) to 8.44, marking a decrease of 0.32.
- For Return On Assets (%), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 5. It has decreased from 1.77 (Mar 24) to 1.25, marking a decrease of 0.52.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.65. This value is within the healthy range. It has increased from 0.58 (Mar 24) to 0.65, marking an increase of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.09. This value exceeds the healthy maximum of 1. It has increased from 0.81 (Mar 24) to 1.09, marking an increase of 0.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has decreased from 0.75 (Mar 24) to 0.71, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 1.5. It has decreased from 0.91 (Mar 24) to 0.80, marking a decrease of 0.11.
- For Quick Ratio (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.85 (Mar 24) to 0.75, marking a decrease of 0.10.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.73. This value is below the healthy minimum of 3. It has decreased from 3.19 (Mar 24) to 2.73, marking a decrease of 0.46.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 3. It has decreased from 1.34 (Mar 24) to 1.31, marking a decrease of 0.03.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8,223.62. It has increased from 5,119.81 (Mar 24) to 8,223.62, marking an increase of 3,103.81.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.70. This value exceeds the healthy maximum of 3. It has increased from 2.68 (Mar 24) to 3.70, marking an increase of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 19.48. This value exceeds the healthy maximum of 15. It has increased from 14.77 (Mar 24) to 19.48, marking an increase of 4.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.37. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 24) to 3.37, marking an increase of 0.90.
- For Price / BV (X), as of Mar 25, the value is 8.13. This value exceeds the healthy maximum of 3. It has increased from 5.70 (Mar 24) to 8.13, marking an increase of 2.43.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.37. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 24) to 3.37, marking an increase of 0.90.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Healthcare Global Enterprises Ltd:
- Net Profit Margin: 2.16%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.44% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.81% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.31
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.75
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 279 (Industry average Stock P/E: 92.28)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.16%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | HCG Tower, Bengaluru Karnataka 560027 | investors@hcgel.com https://www.hcgoncology.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. B S Ajai Kumar | Executive Chairman |
| Dr. Manish Mattoo | Executive Director & CEO |
| Ms. Anjali Ajaikumar | Non Exe.Non Ind.Director |
| Mr. Akshay Tanna | Non Exe.Non Ind.Director |
| Ms. Simrun Mehta | Non Exe.Non Ind.Director |
| Ms. Geeta Mathur | Ind. Non-Executive Director |
| Mr. Pradip Kanakia | Ind. Non-Executive Director |
| Mr. Rajiv Maliwal | Ind. Non-Executive Director |
| Mr. Raj Raghavan | Ind. Non-Executive Director |
| Mr. Bijou Kurien | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Healthcare Global Enterprises Ltd?
Healthcare Global Enterprises Ltd's intrinsic value (as of 18 December 2025) is 764.14 which is 9.16% higher the current market price of 700.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 9,867 Cr. market cap, FY2025-2026 high/low of 805/457, reserves of ₹780 Cr, and liabilities of 3,586 Cr.
What is the Market Cap of Healthcare Global Enterprises Ltd?
The Market Cap of Healthcare Global Enterprises Ltd is 9,867 Cr..
What is the current Stock Price of Healthcare Global Enterprises Ltd as on 18 December 2025?
The current stock price of Healthcare Global Enterprises Ltd as on 18 December 2025 is 700.
What is the High / Low of Healthcare Global Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Healthcare Global Enterprises Ltd stocks is 805/457.
What is the Stock P/E of Healthcare Global Enterprises Ltd?
The Stock P/E of Healthcare Global Enterprises Ltd is 279.
What is the Book Value of Healthcare Global Enterprises Ltd?
The Book Value of Healthcare Global Enterprises Ltd is 65.3.
What is the Dividend Yield of Healthcare Global Enterprises Ltd?
The Dividend Yield of Healthcare Global Enterprises Ltd is 0.00 %.
What is the ROCE of Healthcare Global Enterprises Ltd?
The ROCE of Healthcare Global Enterprises Ltd is 8.56 %.
What is the ROE of Healthcare Global Enterprises Ltd?
The ROE of Healthcare Global Enterprises Ltd is 5.14 %.
What is the Face Value of Healthcare Global Enterprises Ltd?
The Face Value of Healthcare Global Enterprises Ltd is 10.0.